Good Vita / The learning library

CJC-1295

A research compound appearing in growth-hormone-related discussions.

Educational information only. No medical advice or treatment recommendations.

← Back to the full library

Research compounds Early human study Hormone research

Also discussed as: CJC1295

What it is and how it works

CJC-1295 is a long-acting growth hormone-releasing hormone analogue. The cited human study examined whether it produced sustained changes in growth hormone and IGF-1. A biomarker response is a biological finding, not a measurement of better recovery or longer life.

Source for the mechanism context →

A closer look at the cited evidence

Early human study

This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.

Study or assessment
Teichman et al., 2006 — CJC-1295 in healthy adults
Design
Randomized, placebo-controlled, ascending-exposure studies.
Who or what was studied
Healthy adults; the study measured hormone-related responses.
What was observed
CJC-1295 produced sustained increases in growth hormone and IGF-1.
Limits of interpretation
The study did not establish long-term anti-aging, athletic recovery, or functional benefits. Names used for different CJC-related products may conceal molecular differences.
Read the cited study or assessment →

What the evidence means

A laboratory or hormone measurement is not itself proof of better function, recovery, or longer life.

Approval and regulatory context

Not an FDA-approved anti-aging or performance medicine.

Safety and uncertainty

Reported concerns include cardiovascular reactions.

What remains uncertain

The key missing link is whether changing these biomarkers improves meaningful outcomes with an acceptable safety profile. Results for one studied analogue cannot be generalized to every product marketed under a similar name.

These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.

Sources behind this overview

Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.

Start Your Assessment